Samsung Bioepis has submitted a biosimilar version of Roche's breast cancer blockbuster Herceptin in the EU, hard on the heels of rivals Biocon and Mylan.
Hanmi Pharma gained one big deal with Roche this week but lost another tie-up with Boehringer--and investors didn't like it one bit.
The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…
Who are the world's richest billionaires? According to Forbes' latest list, 22 people with pharma interests made the top 500, and Asian drug magnates…
With forced price cuts for brands such as Gilead Sciences' hep C med Sovaldi already under its belt, the Japanese government is weighing others to help…
Dr. Reddy's will sell three of Amgen's already-approved drugs in India, extending an earlier deal involving three late-stage pipeline candidates.
Chairman Zhou Jie resigns just three months after taking on the role.
Chinese-American diagnostics specialist says it is building a new La Jolla lab to support U.S. product launches.
Chinese development venture will boost biotech R&D space in South San Francisco by a fifth, says city manager.
Lupin may be pondering whether it can conclude a deal signaled in July last year to buy 100% of Russian generic drug maker ZAO Biocom.
Zhejiang Hisun will handle greater China efforts on GEN-1 from Celsion in an expanded partnership aimed at costs and faster approvals.